BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a commercial-stage biotech that discovers and commercializes small-molecule and injectable protein therapeutics for rare diseases, anchored by ORLADEYO, the first oral prophylactic therapy for hereditary angioedema, serving HAE patients globally through direct US sales and international licensing partnerships.
- Company typePublic
- Founded1986
- HeadquartersDurham, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioCryst Pharmaceuticals does
BioCryst Pharmaceuticals is a commercial-stage biotechnology company headquartered in Durham, North Carolina, founded in 1986. The company discovers, develops, and commercializes small-molecule and injectable protein therapeutics for rare diseases, using a proprietary structure-guided drug design platform that integrates X-ray crystallography, cryo-EM, computer modeling, virtual screening, and molecular dynamics simulations to design molecules atom-by-atom for optimal target binding. Its commercial portfolio is anchored by ORLADEYO (berotralstat), the first and only FDA-approved oral plasma kallikrein inhibitor for prophylactic treatment of hereditary angioedema in patients aged 2 and older, and RAPIVAB (peramivir), an injectable neuraminidase inhibitor for acute uncomplicated influenza. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE, acquired through the January 2026 Astria Therapeutics transaction), BCX17725 (Phase 1 KLK5 inhibitor for Netherton syndrome), and STAR-0310 (Phase 1 anti-OX40 antibody for atopic dermatitis).
BioCryst generates revenue primarily through direct US commercialization of ORLADEYO via a specialty sales force targeting allergists, immunologists, and specialty pharmacies, supplemented by international distribution and licensing partnerships (Neopharmed Gentili for Europe, plus regional distributors across MEA, LATAM, and APAC). ORLADEYO pricing is set at specialty rare-disease levels ($48,487.92 per 28-day pack as of January 2026), reflecting its orphan indication status and limited oral competition. FY2025 revenue reached $874.8M (94% YoY) with ORLADEYO contributing $601.8M (+38% YoY) and the European ORLADEYO divestiture adding ~$250M; the company achieved its first net income of $263.86M in 2025. The 2026 European licensing deal for navenibart (up to $345M in upfront and milestones plus 18-30% tiered royalties) and the Astria Therapeutics acquisition materially expand both the pipeline and international commercial footprint. The customer base consists of patients with rare genetic conditions (HAE prevalence 1:10,000-1:50,000, plus the much smaller Netherton syndrome population), making the therapeutic categories commercially constrained but defensible through regulatory exclusivity and physician/patient persistence.
BioCryst Pharmaceuticals firmographics
Firmographics- Name
- BioCryst Pharmaceuticals
- Legal name
- BioCryst Pharmaceuticals, Inc.
- Website
- https://biocryst.com
- Company type
- Public
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BioCryst Pharmaceuticals is a commercial-stage biotech that discovers and commercializes small-molecule and injectable protein therapeutics for rare diseases, anchored by ORLADEYO, the first oral prophylactic therapy for hereditary angioedema, serving HAE patients globally through direct US sales and international licensing partnerships.
- Ownership category
- akta.pro rank
BioCryst Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where BioCryst Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
BioCryst Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- ORLADEYO (berotralstat) Sales: Primary revenue driver from sales of ORLADEYO, an oral prophylactic therapy for hereditary angioedema. Generated approximately $601.8 million in full-year 2025 revenue, up 38% year-over-year. Q4 2025 sales of approximately $151 million. Q1 2026 revenue of $148.3 million representing 11% year-over-year growth. The company projects 2026 revenue guidance of $625-645 million.
- European Licensing - Navenibart: Licensing revenue from Neopharmed Gentili for European commercial rights to navenibart. Received $70 million upfront with potential milestone payments up to $275 million and tiered royalties of 18-30% on net sales.
- European ORLADEYO Divestiture: In 2025, BioCryst sold its European ORLADEYO business to Neopharmed Gentili for approximately $250 million upfront plus potential additional considerations, contributing to the 94% revenue increase to $874.8 million in 2025.
- RAPIVAB (peramivir injection): Revenue from sales of RAPIVAB, an influenza treatment. Secondary product alongside the primary ORLADEYO franchise.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | ORLADEYO 28-day pack pricing at $48,487.92 |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
BioCryst Pharmaceuticals product offering
Product offeringCore offering
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and commercializes small-molecule and injectable protein therapeutics for rare diseases. Its marketed products include ORLADEYO (berotralstat), the first and only targeted oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) in patients aged 2 and older, and RAPIVAB (peramivir injection), a neuraminidase inhibitor for acute uncomplicated influenza. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE), BCX17725 (KLK5 inhibitor for Netherton syndrome), and STAR-0310 (anti-OX40 antibody for atopic dermatitis).
Product overview
BioCryst Pharmaceuticals is a commercial-stage biotech company with a portfolio of approved and pipeline therapeutics for rare diseases. The core commercial products include ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for hereditary angioedema (HAE) available for adults and children aged 2+, and RAPIVAB (peramivir), an influenza treatment. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE acquired from Astria Therapeutics), BCX17725 (Phase 1 for Netherton syndrome), and STAR-0310 (Phase 1 for atopic dermatitis, also from Astria acquisition). The company uses structure-guided drug design to develop oral small-molecule and injectable protein therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- ORLADEYO (berotralstat) An oral plasma kallikrein inhibitor indicated for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older; also available as an oral pellet formulation approved for pediatric patients aged 2 to under 12 years. It is the first and only targeted oral prophylactic therapy for HAE.
- RAPIVAB (peramivir injection) An influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days.
- Navenibart (STAR-0215) A monoclonal antibody plasma kallikrein inhibitor in Phase 3 development (ALPHA-ORBIT) for prophylaxis of hereditary angioedema, offering potential long-acting therapeutic option with every-three and every-six month dosing. Acquired through the January 2026 Astria Therapeutics acquisition.
- BCX17725 A KLK5 inhibitor protein therapeutic in Phase 1 development for the potential treatment of Netherton syndrome, a rare genetic skin disorder with no currently approved treatments.
- STAR-0310 An anti-OX40 half-life extended monoclonal antibody in Phase 1 development for the potential treatment of atopic dermatitis. Acquired through the Astria Therapeutics transaction.
Quantifiable outcome
- ORLADEYO reduced median HAE attack rates from 0.691 to 0.169 per month in pediatric patients aged 2 to <12 years over 48 weeks of treatment
- +4 more outcomes
Companies that use BioCryst Pharmaceuticals
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
BioCryst Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioCryst Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Neopharmed GentilicoreLicensing agreement granting Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart across Europe. BioCryst receives $70 million upfront, up to $275 million in regulatory and sales milestone payments, and tiered royalties of 18% to 30% on net sales. Builds on prior 2025 transaction where Neopharmed Gentili acquired BioCryst's European ORLADEYO business.
- Astria TherapeuticscoreBioCryst completed acquisition of Astria Therapeutics for approximately $700 million in January 2026, financed through cash on hand, a $396.6 million Blackstone financing facility, and issuance of 37.3 million BioCryst shares. The acquisition added navenibart (Phase 3 plasma kallikrein inhibitor for HAE) and early-stage atopic dermatitis program STAR-0310 to BioCryst's portfolio. Astria's CEO Jill C. Milne joined BioCryst's Board of Directors.
- Neopharmed GentilicoreSale of European ORLADEYO business to Neopharmed Gentili for approximately $250 million upfront with potential additional milestone considerations. Transaction completed October 2025.
- Neopharm GroupminorInternational distribution partnership for commercialization of ORLADEYO outside the United States.
- NewBridge PharmaceuticalsminorInternational distribution partnership for commercialization of ORLADEYO outside the United States.
- Pint PharmaminorInternational distribution partnership for commercialization of ORLADEYO outside the United States.
- Swixx BioPharmaminorInternational distribution partnership for commercialization of ORLADEYO outside the United States.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
BioCryst Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Takeda Pharmaceutical: Takeda markets Takhzyzo (lanadelumab), a leading HAE prophylactic therapy and the most direct competitor to BioCryst's ORLADEYO and the navenibart pipeline asset.
- Pharming Group: Pharming markets RUCONEST (C1 esterase inhibitor) for acute HAE attacks and is developing leniolisib, directly competing in the HAE therapeutic space and in rare immunology.
- CSL Behring: CSL Behring markets HAEGARDA, a subcutaneous C1 esterase inhibitor widely used for HAE prophylaxis, directly competing with ORLADEYO for HAE share.
- KalVista Pharmaceuticals: KalVista is developing oral plasma kallikrein inhibitors for HAE, making it a direct pipeline competitor to ORLADEYO and to BioCryst's HAE franchise.
Broad incumbents
- Ionis Pharmaceuticals: Ionis is a leading RNA-targeted rare disease company with a broad specialty/rare disease pipeline, comparable to BioCryst's structure-guided approach and rare disease focus.
- Alnylam Pharmaceuticals: Alnylam is a commercial-stage RNAi therapeutics company with rare disease franchises and global partnerships, comparable in commercial maturity, royalty/licensing model, and rare disease focus.
- Vertex Pharmaceuticals: Vertex is a profitable rare disease-focused biopharma with specialty commercial capabilities, comparable as a profitable, focused rare disease commercial-stage company with active pipeline expansion.
- Regeneron Pharmaceuticals: Regeneron has a large specialty/rare disease franchise and monoclonal antibody expertise, relevant to BioCryst as it advances navenibart, a plasma kallikrein mAb, in HAE.
- BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease company with a similar focus on small patient populations and specialty pricing, comparable in business model and orphan disease focus.
Emerging players
- Intellia Therapeutics: Intellia is an early- to mid-stage genetic medicine company targeting rare diseases; relevant as an emerging rare disease therapeutic peer with a technology platform approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
BioCryst Pharmaceuticals social profiles
Digital presenceBioCryst Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCryst Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles17 records
BioCryst Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries4 records
BioCryst Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds19 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCryst Pharmaceuticals M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCryst Pharmaceuticals
What does BioCryst Pharmaceuticals do?
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops, and commercializes small-molecule and injectable protein therapeutics for rare diseases. Its marketed products include ORLADEYO (berotralstat), the first and only targeted oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) in patients aged 2 and older, and RAPIVAB (peramivir injection), a neuraminidase inhibitor for acute uncomplicated influenza. The pipeline includes navenibart (Phase 3 monoclonal antibody for HAE), BCX17725 (KLK5 inhibitor for Netherton syndrome), and STAR-0310 (anti-OX40 antibody for atopic dermatitis).
Is BioCryst Pharmaceuticals a public or private company?
BioCryst Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was BioCryst Pharmaceuticals founded?
BioCryst Pharmaceuticals was founded in 1986. It employs 501 to 1,000 people.
Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals is headquartered in Durham, United States, in the North America region.
How does BioCryst Pharmaceuticals make money?
Four revenue lines are on record. ORLADEYO (berotralstat) Sales are the primary driver. The others are european Licensing - Navenibart, european ORLADEYO Divestiture and RAPIVAB (peramivir injection).
Who are BioCryst Pharmaceuticals's main competitors?
Direct peers on record are Takeda Pharmaceutical, Pharming Group, CSL Behring and KalVista Pharmaceuticals. Broad incumbents are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Regeneron Pharmaceuticals and BioMarin Pharmaceutical. Intellia Therapeutics is listed as an emerging player.
Does BioCryst Pharmaceuticals have an API?
No public API is recorded for BioCryst Pharmaceuticals.
What industry is BioCryst Pharmaceuticals in?
BioCryst Pharmaceuticals's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.